| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J2505 |
Injection, pegfilgrastim, 6 mg |
906 |
551 |
$3.61M |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
785 |
437 |
$3.17M |
| J1453 |
Injection, fosaprepitant, 1 mg |
1,554 |
806 |
$398K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,464 |
6,119 |
$329K |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
452 |
407 |
$217K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
3,093 |
1,890 |
$152K |
| 96367 |
|
1,695 |
994 |
$104K |
| 96415 |
|
1,659 |
1,124 |
$100K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,020 |
1,013 |
$48K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,427 |
742 |
$38K |
| 96417 |
|
917 |
668 |
$31K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,480 |
3,716 |
$25K |
| J1442 |
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram |
53 |
12 |
$22K |
| J3489 |
Injection, zoledronic acid, 1 mg |
477 |
363 |
$22K |
| 96368 |
|
1,484 |
864 |
$21K |
| J9171 |
Injection, docetaxel, 1 mg |
94 |
50 |
$20K |
| J9070 |
Cyclophosphamide, 100 mg |
29 |
13 |
$13K |
| J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units |
27 |
12 |
$9K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,737 |
889 |
$7K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
440 |
352 |
$6K |
| 99205 |
Prolong outpt/office vis |
44 |
44 |
$5K |
| 99070 |
|
802 |
528 |
$4K |
| 96402 |
|
444 |
429 |
$4K |
| 96401 |
|
21 |
13 |
$112.98 |